Business Wire

Mycala Partners with TV Berlin to Showcase Chinese Film and Culture

Share

Chinese cinema made a splash at the 73rd Berlin International Film Festival this week, with over ten Chinese films selected for the competition and screening sections. These works showcased the creativity and perspectives of Chinese filmmakers across a wide range of subjects, marking a resounding return after the disruptions of the pandemic.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230224005250/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Ms. Shi Yan, Founder & President of Mycala, walks the 73rd Berlinale’s red carpet (Photo: Business Wire)

To promote public interest in Chinese films, Mycala has partnered with TV Berlin to produce a special program (https://youtu.be/E0Sl3RJ4C1w) featuring interviews with the directors of three Chinese films competing or shown at this year's festival.

"By sharing outstanding Chinese films and the creative process behind them with a wider international audience, we hope to broaden understanding of Chinese culture and people’s life," said Shi Yan, Founder and President of Mycala. "The art of cinema creates bridges of communication with the audience as the language of the camera conveys emotion and awakens empathy."

The three films selected into this special program are Wu Lang’s Absence” from the Encounters section, Mad Fate” by Hong Kong director Soi Cheang screened in the Berlinale Special, and Zhang Dalei's All Tomorrow's Parties”, that competes in the Berlinale Shorts starring Zhou Xun and Wang Yibo.

In these interviews, the filmmakers discuss the creative process and emotional themes behind their works, personal experiences on their journeys through cinema, and thoughts on the future of the film industry.

Founded in Berlin in 2008, Mycala specializes in cross-border operations and distribution for high-end brands, representing over 60 international brands in the Asia market, focusing on China. Mycala is committed to the pursuit of fashion and high quality of life, creating value through cutting-edge ideas and technology. In recent years, the company has worked to promote cultural exchange between China and abroad, creating online and offline platforms for communication and interaction that have gained recognition both in China and overseas.

At this year's Berlinale, Shi Yan walked the red carpet as the only Chinese VIP invited by Armani Beauty, the principal partner of the festival.

"The art of cinema is an integral part of high-quality living and an important vehicle for cross-cultural understanding and communication," she said. "Supporting exchanges in the cultural field, including the film industry, is aligned with Mycala's vision to lead in fashion and help people pursue high-quality lives through new ideas, technology, and values."

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Shelly Wang
contact@panoramist-consulting.de

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 03:00:00 EET | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn

Enry's Island SpA Strengthens Its Leadership in Venture Capital with Explosive Growth and Redesigns the Future of VC Through Gaming19.12.2025 01:34:00 EET | Press release

Enry’s Island SpA (WBAG:EIOS), the world’s first publicly listed venture builder, announces a new era of growth, innovation, and the democratization of Venture Capital (VC). The company has delivered exceptional results, consolidating its position as an industry leader through a strategic positioning in the rapidly expanding gaming market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218742236/en/ Record Growth and Performance Enry’s Island SpA has demonstrated an extraordinary growth trajectory and a strong financial and operational track record: Revenues: +250% year-over-year (YoY). Exit: $3.6M in exits realized via IPO. Portfolio: 1 IPO of a portfolio company completed in December 2024, with an additional 2 IPOs expected in 2026. The performance of the EIOS:VSE stock reflects this strength: Price per Share (PPS): +132% in the first half (H1) of 2025, stabilizing at a +116% YTD increase. Daily Trading Volume: peaks of

500 Global Expands Africa Presence; Selected to Advance Digital Morocco 2030 Strategy18.12.2025 22:37:00 EET | Press release

500 Global, one of the world’s most active venture capital firms1, announced it has been selected to support the Ministry-led Startup VB initiative, a flagship program under the Digital Morocco 2030 strategy2. This announcement marks a significant milestone in 500 Global’s continued expansion across the African continent and its work collaborating with governments to strengthen national innovation ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218363323/en/ Announcement of 500 Global's continued expansion across Africa and support of Digital Morocco 2030 Launched by the Ministry of Digital Transition and Administrative Reform (Ministry) and deployed by TAMWILCOM, the Startup VB initiative is a flagship program under the Digital Morocco 2030 strategy. Startup VB aims to strengthen Morocco’s innovation and digital competitiveness by accelerating high-potential founders and providing the training and financing pa

Neural Concept Closes $100M Funding Round Led by Growth Equity at Goldman Sachs Alternatives to Scale AI-Native Engineering18.12.2025 18:00:00 EET | Press release

Neural Concept, a global AI platform and leader in Engineering Intelligence powering next-generation product development, today announced it raised a $100 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives, with existing investors Forestay Capital, Alven, HTGF, D.E. Shaw Ventures and Aster Capital. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218764112/en/ Image courtesy of Neural Concept (L-R clockwise from top) Jonathan Donier, CSO & Co-founder; Thomas von Tschammer, Managing Director US & Co-founder; Théophile Allard, CTO & Co-founder; Pierre Baqué CEO & Co-founder; Philippe Cuendet, COO Neural Concept is redefining engineering workflows with CAD-native enterprise AI that understands geometry, constraints and design intent. By helping its customers build and deploy physics-aware design copilots, the platform enables teams to explore millions of design options earlier and avoid costly la

Croma-Pharma Introduces New Medical Device for the Preparation of Autologous PRP | Fluid- PRF18.12.2025 17:57:00 EET | Press release

Croma-Pharma, a global player in minimally invasive aesthetic medicine, proudly announces the launch of its new medical device that is used for the preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin (Fluid-PRF).1 This launch represents continued progress in Croma’s mission to provide healthcare professionals state-of-the-art tools for their practice. With its innovative design and optimized separation technology, Exprecell™ enables the efficient preparation of autologous blood concentrates, without the use of anticoagulants, resulting in the formation of Fluid-PRF, a biologically active concentrate that retains the regenerative properties of platelets and leukocytes, yet stays liquid for a defined period.1 What makes Exprecell™ special? MDR certification: Exprecell™ is MDR-certified, meeting stringent EU regulatory requirements to ensure the safe, controlled and standardized preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye